These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30702211)

  • 21. Spray-freeze-dried inhalable composite microparticles containing nanoparticles of combinational drugs for potential treatment of lung infections caused by Pseudomonas aeruginosa.
    Yu S; Pu X; Ahmed MU; Yu HH; Mutukuri TT; Li J; Zhou QT
    Int J Pharm; 2021 Dec; 610():121160. PubMed ID: 34624446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dry powder inhalation containing muco-inert ciprofloxacin and colistin co-loaded liposomes for pulmonary P. Aeruginosa biofilm eradication.
    Wang J; Guo Y; Lu W; Liu X; Zhang J; Sun J; Chai G
    Int J Pharm; 2024 Jun; 658():124208. PubMed ID: 38723731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
    Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
    Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
    McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
    Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation.
    Davies JC; Sermet-Gaudelus I; Naehrlich L; Harris RS; Campbell D; Ahluwalia N; Short C; Haseltine E; Panorchan P; Saunders C; Owen CA; Wainwright CE;
    J Cyst Fibros; 2021 Jan; 20(1):68-77. PubMed ID: 32967799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of Ciprofloxacin and Its Copper Complex against Pseudomonas aeruginosa Biofilms.
    Tewes F; Bahamondez-Canas TF; Smyth HDC
    AAPS PharmSciTech; 2019 May; 20(5):205. PubMed ID: 31144198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved effect of amikacin-loaded poly(D,L-lactide-co-glycolide) nanoparticles against planktonic and biofilm cells of Pseudomonas aeruginosa.
    Sabaeifard P; Abdi-Ali A; Gamazo C; Irache JM; Soudi MR
    J Med Microbiol; 2017 Mar; 66(2):137-148. PubMed ID: 28260589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibiotic exposure and interpersonal variance mask the effect of ivacaftor on respiratory microbiota composition.
    Peleg AY; Choo JM; Langan KM; Edgeworth D; Keating D; Wilson J; Rogers GB; Kotsimbos T
    J Cyst Fibros; 2018 Jan; 17(1):50-56. PubMed ID: 29042177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.
    Elborn JS; Ramsey BW; Boyle MP; Konstan MW; Huang X; Marigowda G; Waltz D; Wainwright CE;
    Lancet Respir Med; 2016 Aug; 4(8):617-626. PubMed ID: 27298017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters.
    Millar BC; McCaughan J; Rendall JC; Downey DG; Moore JE
    J Clin Pharm Ther; 2018 Feb; 43(1):92-100. PubMed ID: 29293275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Zingerone inhibit biofilm formation and improve antibiofilm efficacy of ciprofloxacin against Pseudomonas aeruginosa PAO1.
    Kumar L; Chhibber S; Harjai K
    Fitoterapia; 2013 Oct; 90():73-8. PubMed ID: 23831483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Formation of hydroxyl radicals contributes to the bactericidal activity of ciprofloxacin against Pseudomonas aeruginosa biofilms.
    Jensen PØ; Briales A; Brochmann RP; Wang H; Kragh KN; Kolpen M; Hempel C; Bjarnsholt T; Høiby N; Ciofu O
    Pathog Dis; 2014 Apr; 70(3):440-3. PubMed ID: 24376174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections.
    Hisert KB; Heltshe SL; Pope C; Jorth P; Wu X; Edwards RM; Radey M; Accurso FJ; Wolter DJ; Cooke G; Adam RJ; Carter S; Grogan B; Launspach JL; Donnelly SC; Gallagher CG; Bruce JE; Stoltz DA; Welsh MJ; Hoffman LR; McKone EF; Singh PK
    Am J Respir Crit Care Med; 2017 Jun; 195(12):1617-1628. PubMed ID: 28222269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Poly-Lactic-Co-Glycolic Acid Micro- and Nanoparticles of Ciprofloxacin Against Bacterial Biofilms.
    Thomas N; Thorn C; Richter K; Thierry B; Prestidge C
    J Pharm Sci; 2016 Oct; 105(10):3115-3122. PubMed ID: 27519649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incorporation of Farnesol Significantly Increases the Efficacy of Liposomal Ciprofloxacin against Pseudomonas aeruginosa Biofilms in Vitro.
    Bandara HM; Herpin MJ; Kolacny D; Harb A; Romanovicz D; Smyth HD
    Mol Pharm; 2016 Aug; 13(8):2760-70. PubMed ID: 27383205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unveiling the early events of Pseudomonas aeruginosa adaptation in cystic fibrosis airway environment using a long-term in vitro maintenance.
    Sousa AM; Monteiro R; Pereira MO
    Int J Med Microbiol; 2018 Dec; 308(8):1053-1064. PubMed ID: 30377031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy.
    Lommatzsch ST; Taylor-Cousar JL
    Ther Adv Respir Dis; 2019; 13():1753466619844424. PubMed ID: 31027466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repurposing Ivacaftor for treatment of Staphylococcus aureus infections.
    Thakare R; Singh AK; Das S; Vasudevan N; Jachak GR; Reddy DS; Dasgupta A; Chopra S
    Int J Antimicrob Agents; 2017 Sep; 50(3):389-392. PubMed ID: 28694231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
    Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
    N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enzyme-encapsulating polymeric nanoparticles: A potential adjunctive therapy in Pseudomonas aeruginosa biofilm-associated infection treatment.
    Han C; Goodwine J; Romero N; Steck KS; Sauer K; Doiron A
    Colloids Surf B Biointerfaces; 2019 Dec; 184():110512. PubMed ID: 31563809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.